title: The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
abstract: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Currently, cariprazine is in late-stage clinical development (phase III clinical trials) in patients with schizophrenia (S) and in patients with bipolar disorder (BD), as well as an adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. Cariprazine has completed phase III trials for the acute treatment of schizophrenia and bipolar mania, phase II trials for the bipolar depression and MDD whilst it is undergoing phase III trials as an adjunct to antidepressants. The present review aims at proving a comprehensive summary of the current evidence on the safety, tolerability and efficacy of cariprazine in the treatment of schizophrenia, BD (manic/mixed/ depressive episode) and MDD. A systematic search was conducted on PubMed/Medline/ Scopus and the database on Clinical Trials from inception until April 2015 by typing a set of specified keywords. Available evidence seems to support cariprazine efficacy in the treatment of cognitive and negative symptoms of schizophrenia. Preliminary findings suggest its antimanic activity whilst it is still under investigation its efficacy in the treatment of bipolar depression and MDD. Furthermore, the available data seems not to allow judgements about its antipsychotic potential in comparison with currently prescribed antipsychotics. Further studies should be carried out to better investigate its pharmacodynamic and clinical potential, particularly as alternative to current antipsychotic drugs.
authors.affiliation: National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, "G. Mazzini" Hospital, p.zza Italia 1, 64100 Teramo, Italy. dodebera@alice.it.
authors.forename: Domenico
authors.initials: D
authors.lastname: De Berardis
authors.forename: Laura
authors.initials: L
authors.lastname: Orsolini
authors.forename: Felice
authors.initials: F
authors.lastname: Iasevoli
authors.forename: Emiliano
authors.initials: E
authors.lastname: Prinzivalli
authors.forename: Andrea
authors.initials: A
authors.lastname: de Bartolomeis
authors.forename: Nicola
authors.initials: N
authors.lastname: Serroni
authors.forename: Monica
authors.initials: M
authors.lastname: Mazza
authors.forename: Alessandro
authors.initials: A
authors.lastname: Valchera
authors.forename: Michele
authors.initials: M
authors.lastname: Fornaro
authors.forename: Roberta
authors.initials: R
authors.lastname: Vecchiotti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Carano
authors.forename: Gianna
authors.initials: G
authors.lastname: Sepede
authors.forename: Federica
authors.initials: F
authors.lastname: Vellante
authors.forename: Ilaria
authors.initials: I
authors.lastname: Matarazzo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Pompili
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Perna
authors.forename: Chiara
authors.initials: C
authors.lastname: Conti
authors.forename: Cristina
authors.initials: C
authors.lastname: Segura-García
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinotti
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Giannantonio
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; C533287:cariprazine